Trial Profile
Anlotinib Combined With Docetaxel For Advanced Non-Small Cell Lung Cancer After The Failure Of Platinum-Based Doublet-Chemotherapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ACDFNSCLC
- 17 Nov 2018 New trial record